Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia by Alshammari, Tk et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Alshammari, TK; Alshammari, MA; Nenov, MN; Hoxha, E; Cambiaghi M;
Marcinno, A; James, TF; Singh, P; Labate, D; Li, J; Meltzer, HY; Sacchetti,
B; Tempia, F; Laezza, F. Genetic deletion of fibroblast growth factor 14
recapitulates phenotypic alterations underlying cognitive impairment
associated with schizophrenia. TRANSLATIONAL PSYCHIATRY. 6 (e806)
pp: 1-10.
DOI: 10.1038/tp.2016.66
The publisher's version is available at:
http://www.nature.com/doifinder/10.1038/tp.2016.66
When citing, please refer to the published version.




Genetic deletion of fibroblast growth factor 14 recapitulates
phenotypic alterations underlying cognitive impairment
associated with schizophrenia
TK Alshammari1,2,3,10, MA Alshammari1,2,3,10, MN Nenov2, E Hoxha4,5, M Cambiaghi5, A Marcinno4, TF James5, P Singh6, D Labate6,
J Li7,8, HY Meltzer7, B Sacchetti5, F Tempia2,4,5 and F Laezza2,8,9
Cognitive processing is highly dependent on the functional integrity of gamma-amino-butyric acid (GABA) interneurons in the
brain. These cells regulate excitability and synaptic plasticity of principal neurons balancing the excitatory/inhibitory tone of cortical
networks. Reduced function of parvalbumin (PV) interneurons and disruption of GABAergic synapses in the cortical circuitry
result in desynchronized network activity associated with cognitive impairment across many psychiatric disorders, including
schizophrenia. However, the mechanisms underlying these complex phenotypes are still poorly understood. Here we show that in
animal models, genetic deletion of fibroblast growth factor 14 (Fgf14), a regulator of neuronal excitability and synaptic transmission,
leads to loss of PV interneurons in the CA1 hippocampal region, a critical area for cognitive function. Strikingly, this cellular
phenotype associates with decreased expression of glutamic acid decarboxylase 67 (GAD67) and vesicular GABA transporter (VGAT)
and also coincides with disrupted CA1 inhibitory circuitry, reduced in vivo gamma frequency oscillations and impaired working
memory. Bioinformatics analysis of schizophrenia transcriptomics revealed functional co-clustering of FGF14 and genes enriched
within the GABAergic pathway along with correlatively decreased expression of FGF14, PVALB, GAD67 and VGAT in the disease
context. These results indicate that Fgf14− /− mice recapitulate salient molecular, cellular, functional and behavioral features
associated with human cognitive impairment, and FGF14 loss of function might be associated with the biology of complex brain
disorders such as schizophrenia.
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INTRODUCTION
Psychiatric diseases such as schizophrenia, depression and bipolar
disorder are associated with cognitive deficits thought to arise
from an imbalance between the excitatory and inhibitory (E/I)
tone in cortical circuits.1,2 Fast-spiking GABAergic parvalbumin
(PV) interneurons have a fundamental role in maintaining E/I
balance, controlling excitability and shaping the synaptic plasticity
of principal neurons.3 Even though disrupted function of other
types of inhibitory neurons has been associated with the etiology
of brain disorders, changes in PV neurons are one of the most
consistent associations. In animal models, reduced function of PV
neurons results in desynchronized network activity, decreased
gamma frequency oscillations and cognitive deficits, phenotypes
that mimic clinical presentation and post-mortem tissue studies of
virtually all human brain disorders associated with disrupted
cognition.1,4–10
In schizophrenia and bipolar patients, the number of PV
interneurons and the expression level of molecular components
of GABAergic synapses, such as glutamic acid decarboxylase 67
(GAD67) and vesicular gamma-amino-butyric acid (GABA) trans-
porter (VGAT), are found decreased in post-mortem brains leading
to the ‘GABA hypofunction hypothesis’ as a potential etiology.1,11–16
Yet, the molecular understanding of how such a detrimental loss
of the GABAergic system might lead to corrupted cortical
networks manifesting in disease, remains poorly explored.
Recent large-scale genome-wide association studies identified
FGF14 as locus of single-nucleotide polymorphisms and as such a
potential disease-associated gene for schizophrenia, bipolar
disease, depression, epilepsy and addictive behaviors,17–27 corro-
borating initial reports of missense mutations in FGF14 as genetic
links to the neurodegenerative disorder, spinocerebellar ataxia
27.28,29 These results highlight the possibility of an as yet
undiscovered and pivotal role for the FGF14 gene in psychiatric
disorders.
Highly expressed in the central nervous system, FGF14 is an
accessory protein of voltage-gated Na+ (Nav) channels at
the axonal initial segment (AIS),30–36 a regulator of neuronal
excitability,30,37–39 a presynaptic organizer of glutamatergic
synapses,40,41 a scaffolding molecule for kinase signaling
pathways33,34,42,43 and a regulator of synaptic plasticity.41,44,45 At
the circuitry and behavioral level, genetic deletion of FGF14 in
Fgf14− /− mice results in presynaptic structural deficits of CA3–CA1
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hippocampal synapses, decreased long-term potentiation, and
cognitive deficits, aberrant responses to epileptic agents and
decreased threshold for seizure induction.41,44,45 Furthermore,
Fgf14− /− mice exhibit abnormal locomotor activity explained by a
reduced response to dopamine receptor D2 agonists in the basal
ganglia.45 Both phenotypes in the hippocampus and the basal
ganglia could imply an impaired GABAergic tone supporting the
emerging view of a tight correlation between the dopamine and
the GABAergic systems.46,47 Yet, evidence of FGF14 control of
GABAergic inhibitory transmission is lacking.
Using a combination of confocal microscopy, patch-clamp
electrophysiology, in vivo local field potential recordings and
behavioral studies, we discovered that genetic deletion of Fgf14 in
rodents leads to a reduced number of PV interneurons, decreased
expression of GAD67 and VGAT, and reduced GABAergic
transmission in CA1 pyramidal neurons associated with impaired
gamma oscillations and working memory. Further, bioinformatics
analysis of schizophrenia transcriptomics confirms FGF14 func-
tional clustering with GABAergic synaptic signaling and identifies
genetic covariance of FGF14, PVALB, GAD67 and VGAT in the
disease, supporting Fgf14− /− mice as an attractive model to
interrogate the biology of complex brain disorders associated with
disrupted cognitive circuitry such as schizophrenia.
MATERIALS AND METHODS
Animals
The primary Fgf14−/− colony was maintained at the animal facilities of the
University of Texas Medical Branch and of the University of Torino
following approved protocols. Genotypes were confirmed by in-house PCR
analysis or by Charles River Laboratories International (Houston, TX, USA).
Description of the animal husbandry is given in the Supplementary
Material.
Immunofluorescence
Brain tissue derived from Fgf14− /− and Fgf14+/+ 4- to 5-month-old male
littermates was processed for immunofluorescence staining using either
4% paraformaldehyde or liquid nitrogen vapor fixation followed by
permeabilization, blocking, and primary and Alexa-conjugated secondary
antibody staining as previously described48 and outlined in the
Supplementary Material.
Data acquisition and image analysis
Multichannel confocal images were acquired using a Zeiss LSM-510 META
(Carl Zeiss Microscopy, Jena, Germany) confocal microscope as previously
described.49 Detailed information on image quantification can be found in
the Supplementary Material.
Western blotting
Tissue homogenate preparation and western blotting were carried out as
previously described50 and outlined in the Supplementary Material.
Whole-cell patch-clamp electrophysiology
Horizontal hippocampal slices were prepared from 4- to 5-month-old
Fgf14− /− and Fgf14+/+ male littermates, and whole-cell patch-clamp
recordings were performed at room temperature from CA1 pyramidal
neurons using standard parameters previously described51,52 and outlined
in the Supplementary Material.
In vivo electroencephalogram
Extracellular field potentials were recorded in freely behaving mice using
stainless steel electrodes stereotaxically implanted in the CA1 of the right
hippocampus.53 Spectrograms were calculated using the software
NeuroExplorer (Nex Technologies, Madison, AL, USA).
Behavioral tests
Tests were performed in Fgf14− /− and Fgf14+/+ 2- to 4-month-old males
using the 4–8 version of the eight-arm radial maze.54 A detailed
description of behavioral experiments and analysis are part of the
Supplementary Material.
Human studies
As a computational gene co-expression search engine, SEEK (http://seek.
princeton.edu/) was applied to identify a gene network co-expressed with
FGF14. Functional annotation and pathway enrichment was performed
with a built-in Gene Ontology and KEGG terms. Enriched data sets were
downloaded from NCBI Gene Expression Omnibus, and the differential
gene expression was analyzed by R Limma packages described in the
Supplementary Material. We also applied GeneMANIA and STRING to the
analysis of pathway enrichment and protein–protein interaction for the co-
expressed genes of FGF14 in hippocampus. The method and result are
detailed in the Supplementary Material.
RESULTS
Anatomical abnormalities found in the CA1 hippocampal region of
post-mortem brains from schizophrenia patients have been
identified as an index of the disease severity and treatment
responsiveness.55 These studies along with the reported associa-
tion between hippocampal PV neurons with cognitive function in
the normal brain and in schizophrenia, prompted us to begin our
investigations in the CA1 hippocampal region.15,16,46,47,55 Thus, we
first asked whether FGF14 was expressed in PV interneurons in the
CA1 region. Confocal imaging confirmed that FGF14 is expressed
at the AIS of cells across all CA1 sublayers (Figure 1a), including
PV-positive neurons (Figure 1b). Therefore, we posited whether
genetic ablation of Fgf14 might have physiological consequences
for these inhibitory neurons.
To test this hypothesis, we first examined whether the overall
number of PV interneurons in the CA1 area was affected by
genetic loss of FGF14. Cell count quantification based on
immunofluorescence staining revealed that the total number of
PV-positive cells was significantly reduced in Fgf14− /− mice
compared with wild-type controls (Figures 1c–e; 74.21%± 5.02,
100%±4.89, Po0.001) with a most pronounced and significant
reduction in the stratum oriens (SO; 71.42%±6.96, 100%± 8.10,
Po0.05) and in stratum pyramidalis (SP; 77.94%±4.96,
100%±7.06, Po0.05; Figure 1f). Notably, the expression level of
PV per cell was not significantly different across groups (P= 0.78,
n= 4 littermate mice; Supplementary Figures 1F–I); the neuropil
composed of PV-positive neurites in either SP or SO was also
unaffected by Fgf14 deletion (P= 0.49 and 0.28; Supplementary
Figures 1A–E). Furthermore, the total number of cells in the CA1
SP, which primarily includes pyramidal neurons, was also
unchanged (P= 0.24; Figures 1j–l). Thus, we concluded that
deletion of Fgf14 leads to a cell- and subfield-specific reduction
in the number of PV neurons in the CA1 hippocampal region.
PV interneurons are the primary source of GABAergic synapses
in the CA1 region. Reduction in GABA synthesis and its synaptic
release machinery accompany loss of PV neurons in schizophrenia
and other psychiatric disorders.4–6 Consistent with this, GAD67
mean fluorescence intensity in PV soma, the primary source of the
enzyme pool, and in puncta across SP was significantly reduced in
Fgf14− /− mice compared with littermate control (89.85%± 3.08,
100%±3.96, Po0.05; and 91.86%± 0.10, 100%±0.08, Po0.0001,
respectively; Supplementary Figures 2A–D and Figures 2a–c). The
area per puncta and total puncta number, though, were
unchanged (P= 0.10 and 0.88, respectively; Figure 2c). An
additional marker and key regulatory protein at presynaptic
GABAergic inputs is VGAT, the vesicular transporter that loads
presynaptic vesicles with GABA, another marker associated with
brain disorders.56–58 Along with GAD67, the mean fluorescence
intensity of VGAT in PV soma and its mean content per puncta in
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SP were significantly decreased in Fgf14− /− mice compared with
littermate controls (88.12%±3.06 vs 100%±3.18, Po0.01, n= 4
littermate mice and 91.92%±0.14 vs 100%±0.135, Po0.001, n= 3
littermate mice, respectively; Supplementary Figures 2E–H and
Figures 2d–f ), while puncta area and number were unchanged
(P= 0.66 and 0.79, n= 3 mice; Figure 2f). Consistent with these
results, Western blot analyses of hippocampal cell lysate revealed
a significant reduction of GAD67 and VGAT protein content in
Fgf14− /− animals compared with wild type (Figures 2g and h).
PV interneurons contribute greatly to the integrity of the
GABAergic circuit in the CA1 region, posing the question of
whether Fgf14 deletion might result in functional consequences
for inhibitory transmission. Using patch-clamp electrophysiology,
we recorded spontaneous and miniature inhibitory postsynaptic
currents (sIPSCs and mIPSCs, respectively) from visually identified
CA1 pyramidal neurons in Fgf14− /− and wild-type control mice
(Figures 3a and f). We found that genetic deletion of Fgf14 led to a
rightward shift in the probability distribution of sIPSC frequency
(apparent loss in the higher frequency domain) accompanied by a
reduction in the largest- and smallest-size synaptic event
population (Figures 3c–e; Po0.001, Kolmogorov–Smirnov test).
Spontaneous IPSCs are action potential-driven synaptic events
and as such represent a compound readout of the firing status of
presynaptic interneurons and their neurotransmitter release
machinery. To examine GABA release mechanisms independently
from interneuron spontaneous firing, we recorded mIPSCs in the
presence of tetrodotoxin and found that, similarly to sIPSCs, the
frequency distribution histograms showed lowered probability of
short inter-event intervals in Fgf14− /− when compared with wild-
type control mice (Figures 3f–h, Po0.001 with Kolmogorov–
Smirnov test). This phenotype was paralleled by a loss of large-
and small-amplitude mIPSCs in Fgf14− /− compared with wild-type
control mice (Figures 3f, i and j). In both sIPSCs and mIPSCs, the
averaged sIPSC frequency and amplitude between the two groups
were not significantly different (Supplementary Figure 3) and no
changes in rise and decay time were found across synaptic events
(both sIPSCs and mIPSCs) of different genetic groups
(Supplementary Figure 4). Thus, genetic deletion of Fgf14 leads
to functional changes in the CA1 inhibitory circuitry that support
the structural alterations demonstrated in Figures 1 and 2.
Moreover, it suggests loss of interneuron firing (shift in sIPSC
frequency) and pre- and postsynaptic modifications at GABA
synapses (shift in frequency and amplitude distribution of mIPSCs,
respectively).
Reduced PV neuron function can desynchronize the CA1
network resulting in reduced gamma oscillations and impaired
cognition. Thus, we postulated that gamma oscillations might be
impaired upon ablation of Fgf14. To test this, gamma oscillations
were recorded in the CA1 SR layer in Fgf14− /− and control mice by
in vivo local field potential (Figure 4a). Spectral analysis within the
30–100 Hz range revealed that Fgf14− /− mice had a strong
reduction in gamma oscillation power (2.94 ± 0.11 μV2, n= 7
compared with 7.92 ± 0.17 μV2, n= 7 in wild-type mice, Po0.05;
Figures 4b and c) with both slow (low gamma, 30–65 Hz) and
fast (high gamma, 65–100 Hz) gamma oscillations significantly
impaired in Fgf14− /− mice compared with wild type (Fgf14− /−− /−,
2.29 ± 0.85 and 0.65 ± 0.25 μV2; wild-type control, 5.97 ± 1.2
and 1.95 ± 0.5 μV2; Figure 4d). Thus, consistent with disrupted
GABAergic transmission, spectral analysis confirmed that FGF14 is
required for the integrity of the cognitive circuitry. The
Figure 1. Genetic deletion of Fgf14 results in structural changes in the CA1 parvalbumin (PV) interneurons. (a) FGF14 immunoreactivity is
detectable at the axonal initial segment (AIS) of cells in CA1. (b) FGF14 (red) expressed in the soma and AIS of PV interneurons (green), i and ii
represent zooms of the boxed area. (c, d) PV interneurons in the CA1 region of Fgf14+/+ and Fgf14− /− mice and respective higher resolution
views of PV somas (i and ii). (e, f) Quantification of total PV interneurons in CA1 (380 cells in Fgf14+/+ and 282 in Fgf14− /−), and in specific
subfields (oriens, pyramidalis and radiatum). Data represent mean± s.e.m., ***Po0.001; **Po0.02; *Po0.05 statistical differences were
assessed by Student’s t-test or non-parametric Mann–Whitney test. Scale bars, 40 μm (a); 10 μm (b); 100 μm (d).
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combination of phenotypes observed in Fgf14− /−mice (Figures 1–4)
has been associated with deficits in spatial working memory in
animal models and patients afflicted with schizophrenia.1,58,59
Thus, we next evaluated the spatial working memory performance
of Fgf14− /− mice using the eight-arm maze test. Analysis of the
latency to perform the task showed that Fgf14− /− mice required a
longer time to complete the task than wild type (n= 20 wild type
and n= 19 Fgf14− /−, Po0.001; Figure 4e). Furthermore, revisiting
errors (Figure 4f), which are directly linked to working memory
performance, were more frequent in Fgf14− /− mice than in
wild types (Po0.05), corroborating the cellular and functional
phenotypes associated with genetic deletion of Fgf14.
To provide translational value to our studies, we examined large
transcriptomic data sets from schizophrenia post-mortem tissues
deposited in the NCBI Gene Expression Omnibus, seeking genes
whose expression might covary with that of FGF14. Through the
SEEK-based gene co-expression search engine with built-in
functional annotation and pathway enrichment by Gene Ontology
terms (Supplementary Table 2) and by KEGG ortholog analysis, we
found that FGF14 was enriched within the ‘GABAergic synapse’
pathway (Supplementary Table 1) and its expression profile
correlated with that of PVALB (P= 0.004 in hippocampus;
P= 0.0059 in prefrontal cortex), GAD67 (P= 0.0009 in hippocam-
pus; P= 0.0003 in prefrontal cortex) and VGAT (P= 0.04 in
Figure 2. The effect of Fgf14 genetic ablation on GABAergic presynaptic proteins in the hippocampal CA1 region. (a, b) GAD67 representative
puncta in CA1 stratum pyramidalis (SP) at high magnification. (c) Quantification of GAD67 puncta area, puncta intensity and puncta number in
the indicated genotypes. (d, e) Vesicular GABA transporter (VGAT) representative puncta in CA1 SP at high magnification. (f) Quantification of
VGAT puncta area, puncta intensity and puncta number in the indicated genotypes. (g) Quantitative western blot analysis of GAD67 and VGAT
from the hippocampus. (h) Immunoblot detection of GAD67 and VGAT in whole hippocampal homogenates from Fgf14− /−mice and Fgf14+/+
controls. Data represent mean± s.e.m., ***Po0.001; **Po0.02; *Po0.05 statistical differences were assessed by Student’s t-test or non-
parametric Mann–Whitney test. Scale bars, 20 μm (a, d). GABA, gamma-amino-butyric acid; GAD67, glutamic acid decarboxylase 67.
Fibroblast growth factor 14 and cognitive function
TK Alshammari et al
4
Translational Psychiatry (2016), 1 – 10
Figure 3. Genetic deletion of Fgf14 impairs GABAergic transmission in the CA1 region. Representative traces of whole-cell patch-clamp
recordings showing effect of Fgf14 ablation on spontaneous inhibitory postsynaptic current (sIPSCs) (a) and miniature inhibitory postsynaptic
current (mIPSCs) (f). (b) Inter-event-interval distribution of spontaneous GABAergic events in Fgf14+/+ (n= 8 cells) and Fgf14− /−(n= 10 cells)
mice. (c) Inter-event-interval cumulative distribution plot for Fgf14+/+ and Fgf14− /−(sIPSCs; ***Po0.001, Kolmogorov–Smirnov test). (d)
Amplitude distribution of spontaneous GABAergic events in Fgf14+/+ (n= 8 cells) and Fgf14− /− (n= 10 cells) mice. (e) Amplitude cumulative
distribution plot for Fgf14+/+ and Fgf14− /− sIPSCs (***Po0.001; Kolmogorov–Smirnov test). (g) Inter-event-interval distribution of miniature
GABAergic events in Fgf14+/+ (n= 6 cells) and Fgf14− /− (n= 7 cells) mice. (h) Inter-event-interval cumulative distribution plot for Fgf14+/+ and
Fgf14− /− mIPSCs (***Po0.001 with Kolmogorov–Smirnov test). (i) Amplitude distribution of miniature GABAergic events in Fgf14+/+ (n= 6
cells) and Fgf14− /− (n= 7 cells) mice. (j) Amplitude cumulative distribution plot for Fgf14+/+ and Fgf14− /− sIPSCs (*Po0.05; Kolmogorov–
Smirnov test).
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hippocampus; P= 0.069 in prefrontal cortex) (Supplementary
Table 3) in tissue/disease-specific conditions including schizo-
phrenia. Western blot analysis confirmed a significant reduction
of GAD67 and VGAT protein expression in the hippocampus
(Figures 2g and h) as well as in the prefrontal cortex
(Supplementary Fig.5A, B) in Fgf14− /− mice compared with
controls, providing further correlations between our mouse model
and human studies. We subsequently analyzed expression of the
FGF14, PVALB, GAD67 and VGAT genes and their correlations in two
schizophrenia-enriched data sets and matched controls from the
dorsal lateral prefrontal cortex.60,61 Both data sets showed a
significant decreased expression of FGF14, PVALB, GAD67 and
VGAT (Figure 5a and Supplementary Figure 6), and a highly
significant correlation between FGF14, PVALB, GAD67 and VGAT
was found in all samples and in schizophrenia alone with the
largest effect size in schizophrenia and controls for GAD67
(Figure 5b). The top enriched pathway such as ‘GABAergic
synapse’ was also confirmed by another pathway enrichment
tool, GeneMANIA and the GABAergic gene cluster was identified
by STRING as showed in Supplementary Table 4 and Supple-
mentary Figure 8.
DISCUSSION
Here we provide new evidence for FGF14 in maintaining
GABAergic activity in the CA1 hippocampal region, an area critical
for cognitive function.65 Genetic deletion of Fgf14 leads to a
decrease in the number of PV interneurons and in the expression
level of the presynaptic GABAergic markers GAD67 and VGAT.
These changes are associated with reduced inhibitory tone of
pyramidal neurons, decreased gamma frequency oscillations and
deficits in working memory. Bioinformatics analysis from human
transcriptomics identified FGF14 as a component of GABAergic
synaptic signaling and revealed a correlated decrease in FGF14,
PVALB, GAD67 and VGAT gene expression in schizophrenia
post-mortem tissues compared with matched controls. These
results provide a new mechanistic role for FGF14, an emerging
neuropsychiatric disease-associated gene17–27 in the context of
human brain disorders.
The identification of FGF14 immunoreactivity at the AIS of CA1
PV interneurons suggests this protein contributes to interneuron
structural and functional diversity66 and as such might be part of
the repertoire of signaling molecules dictating the cell cardinal
and definitive specifications of PV neurons in the neural
circuitry.1,67 The cell type and sublayer-specific loss of PV neurons
observed upon Fgf14 deletion confirms this hypothesis and
supports the notion that FGF14 is indispensable for the
development, maintenance and/or survival of PV interneurons in
the CA1 region. Our post-mortem human tissue study identifies a
significant correlation between the Fgf14 and PVALB genes, which
might contribute to the loss of PV interneurons observed in
Fgf14− /− mice.
We also found that the expression level of GAD67 and VGAT,
two well-characterized disease-associated proteins critical for
GABA synthesis and differentiation in addition to synaptogenesis
of PV neurons,68–71 are decreased in PV-positive somas and at
inhibitory presynaptic terminals in Fgf14− /− animals. This pheno-
type is consistent with a diminished total pool of the two proteins,
Figure 4. Genetic deletion of Fgf14 reduces gamma frequency and affects working memory. (a) Representative traces of 10-s in vivo
electroencephalogram recordings in the CA1 region of hippocampus (local field potential; LFP) in Fgf14+/+ (left) and Fgf14− /− mice (right);
filtered traces within low- and high-gamma band are also shown. (b) Spectrogram analysis of the above-mentioned traces in the gamma
range (30–100 Hz). (c) Mean power spectral density of CA1 activity showing a marked decrease in gamma power in Fgf14− /− (n= 7) with
respect to Fgf14+/+ (n= 7) mice, as revealed by power analysis within both low- and high gamma (d). (e) Fgf14− /− mice required a longer time
to perform the eight-arm maze test (n= 20 wild type and n= 19 Fgf14− /−; Po0.001, t-test). (f) Analysis of working memory errors committed
during the test day showed a significant difference between genotypes (Po0.05, t-test). Data are expressed as mean± s.e.m. *Po0.05.
Fibroblast growth factor 14 and cognitive function
TK Alshammari et al
6
Translational Psychiatry (2016), 1 – 10
which might result from covariance of FGF14, GAD67 and VGAT at
expression level as suggested by our bioinformatics analysis from
schizophrenia samples.
Whether loss of PV neurons and deficits in GABAergic markers
in Fgf14− /− brains occur through causative loops or are separate
coincidental events remains to be determined. Evidence exists for
two separate functions of FGF14 as a regulator of intrinsic
excitability at the AIS30,33,34,37,38,42,43 and a presynaptic
organizer.40,41 Thus, phenotypes observed in Fgf14− /− hippocampi
might arise from disruption of two independent functions of
FGF14: one impairing intrinsic firing of PV neurons, causing cell
death, arrested development and/or aberrant circuitry integration,
and one disrupting the presynaptic GABA machinery (synthesis
and loading) via downregulation of selective markers (that is,
GAD67 and VGAT). Convergence of these disrupted functions
might have fatal consequences for the final specifications and
circuitry integration in PV neurons in the CA1 region. In an Fgf14
null condition, these uncompensated functions could be aggra-
vated by concomitant loss of excitatory inputs, leading to a global
remodeling of PV innervation fields,69 shifting cortical networks
into a high-PV status with reduced plasticity.68
Given that the majority of GABAergic inputs in the CA1 area
arise from PV interneurons, and that GAD67 and VGAT are
essential for the synthesis and loading of GABA at presynaptic
terminals, we posited that Fgf14 genetic deletion might impair
hippocampal inhibitory transmission. Consistently, the distribution
of sIPSC frequency (and amplitude) in Fgf14− /− CA1 pyramidal
neurons was found populated by longer inter-event intervals
compared with Fgf14+/+ suggesting that in Fgf14− /− mice the
remaining inhibitory neurons might fire less than in control
animals. sIPSCs are action potential-driven synaptic events and as
such represent a compound readout of the firing status of
presynaptic interneurons and the neurotransmitter release
machinery. To examine GABA release mechanisms independent
Figure 5. Differential gene expression and correlation of FGF14, PVALB, VGAT and GAD67 in post-mortem control and schizophrenia samples.
(a) The GSE21138 and GSE12649 data sets are both derived from previous studies60,61 and deposited in NCBI Gene Expression Omnibus (GEO).
Owing to significant deviation from the mean (42 s.d.) in FGF14 gene expression (221310_at), five samples were removed from the GSE12649
data set. GPL96 represents Affymetrix Human Genome U133A Array; GPL570 represents Affymetrix Human Genome U133 Plus 2.0 Array.
GPL96 had no probeset selected for VGAT (SLC32A1). The original P-value was adjusted by Benjamini and Hochberg (false discovery rate). The
R-value represents a Pearson Correlation with significance at the 0.01 level (two-tailed). (b) Forest plot illustrates the effect size (logFC) of
differential gene expression of FGF14, PVALB, VGAT and GAD67 between controls and schizophrenia patients in post-mortem dorsolateral
prefrontal cortex (DLPFC) (BA46). Linear model and empirical Bayes method (Limma) was applied for assessing the differential gene
expression of FGF14 and its co-expression genes, including PVALB, GAD67 and VGAT, in two independent data sets (GSE21138 and GSE12649)
deposited in NCBI GEO. LogFC40 suggest decreased gene expression in patients with schizophrenia. The forest plot was created by R rmeta
package. VGAT, vesicular gamma-amino-butyric acid transporter.61–64
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of interneuron spontaneous firing, we isolated mIPSCs. The
distributions of frequency and amplitude of mIPSCs in Fgf14− /−
mice were shifted with loss in short inter-event intervals and in
smallest and largest amplitude events, respectively. These results
highlight a combination of pre- and postsynaptic deficits in
GABAergic transmission possibly induced by lower quantum
content, probability of vesicle release or reduced number of
vesicle, which might arise from structural and/or functional loss
of a subset of inhibitory terminals. The lack in change of rise
and decay time in the Fgf14− /− mice argues against significant
changes in the mechanism of diffusion of GABA across the
synaptic cleft, or in the composition of postsynaptic ionotropic
GABA receptors. However, high-resolution structural analysis is
required for confirmation.
In cortical areas loss in PV neuron function and changes in
GABAergic activity can desynchronize the E/I network leading to
reduced gamma oscillations, a phenotype associated with
schizophrenia and other psychiatric disorders.1,3,72 In vivo electro-
encephalogram local field potential recordings in the CA1 region
revealed that in Fgf14− /− animals the total, slow and fast, gamma
band power was suppressed compared with control mice. These
temporally segregated gamma oscillations reflect information
carried by CA3 Schaffer collaterals and perforant path inputs,
respectively.73–75 Thus, a reduction in both slow and fast gamma
implies that both intra- and extra-hippocampal synaptic inputs
might be compromised, possibly reflecting more widespread
anomalies in Fgf14− /− brains, arising from the prefrontal
cortex–thalamic–hippocampal loop.76 At the behavioral level, we
show that Fgf14− /− animals exhibit impaired spatial working
memory, complementing the array of deficits commonly found in
psychiatric disorders associated with cognitive impairment.59
Human transcriptomics data confirmed functional clustering of
FGF14 with GABAergic signaling and identified a highly correlated
decrease of FGF14, PVALB, GAD67 and VGAT in schizophrenia post-
mortem tissues, indicating possible genetic co-regulation of these
genes. Thus, diminished expression of FGF14 in humans might be
a risk factor for complex brain diseases associated with cognitive
impairment such as schizophrenia. These findings extend the
original studies linking the dominant negative FGF14F145S mis-
sense mutation to the inherited, rare disorder SCA27 to a much
broader set of human brain diseases.
The range of phenotypes from molecular to behavioral
observed in Fgf14− /− mice along with our corroborating human
studies lay the groundwork for new mechanistic hypotheses on
the biology and potential risk factors of cognitive impairment in
schizophrenia and other complex brain disorders associated with
E/I tone imbalance and disrupted development and plasticity of
GABAergic signaling.77 These findings further strengthen the
emerging role of the AIS and its molecular components in the
biology of diseases such as schizophrenia, bipolar disorder and
depression.42
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